PRAX241220P65000
- 3.39
- 0.000.00%
Praxis Precision Medicines Newsroom
Praxis Solutions Welcomes Andre Hatibi as Senior Vice President of Business Development
Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $270
Piper Sandler Gives a Buy Rating to Praxis Precision Medicines (PRAX)
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $114 to $120
Praxis Precision Medicines Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Praxis Precision Medicines: Strong Buy Rating Amid Potential Upside and Robust Pipeline Despite Operational Challenges
HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $120 Price Target
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $114 to $170
Praxis Precision Medicine Analyst Ratings
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
Promising Prospects and Financial Stability: Ritu Baral's Buy Recommendation for Praxis Precision Medicines
Wedbush Raises Praxis Precision Medicines Price Target to $57 From $51, Maintains Neutral Rating
Praxis Precision Medicines, Inc. (PRAX) Q3 2024 Earnings Call Transcript Summary
Praxis Precision Medicines Q3 Net Loss Widens, Collaboration Revenue Falls; Shares Drop Pre-Bell
Optimistic Buy Rating for Praxis Precision Medicines Amid Strategic Pipeline Advancements and Long-term Growth Potential
Praxis Precision Medicines | 10-Q: Q3 2024 Earnings Report
Praxis Precision Medicines | 8-K: Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Praxis Precision Medicines GAAP EPS of -$2.75 Misses by $0.76, Revenue of $0.3M In-line
Express News | Praxis Precision Medicines: Maintains Runway Into 2027
Express News | Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results